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PHARMACOKINETICS AND PHARMACODYNAMICS
Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Recombinant Human Granulocyte Colony Stimulating Factor (Lenograstim) Administration
Naoto Hayashi, MSc, Haruki Kinoshita, MSc, Eiji Yukawa, PhD, and Shun Higuchi, PhD G ranulocyte colony stimulating factor (G-CSF), a 20,000-Dalton glycoprotein hormone, stimulates the proliferation and differentiation of neutropoietic progenitor cells to granulocytes and functionally activates the mature neutrophil. Recently, recombinant DNA technology has made it possible to use recombinant human G-CSF (rhG-CSF, lenograstim) for therapeutic purposes in neutropenia occurring with chemotherapy or radiotherapy. Lenograstim is confirmed to be identical to natural human G-CSF in physicochemical, immunological, and biological quality. 1, 2 Administration of rhG-CSF is mainly subcutaneous because the increase in neutrophil count is higher and the stimulated duration is longer in the case of subcutaneous administration than intravenously with the same dose. 3, 4 The dose dependency of the pharmacodynamic response (increase in neutrophil count) is well known. [3] [4] [5] [6] However, there have been fewer reports about the relationship between pharmacokinetic parameters and pharmacodynamic response in the case of the same dosage being administered.
In this study, we have attempted to reveal the relationship between pharmacokinetics parameters and pharmacodynamic response after subcutaneous administration of 1 µg/kg of rhG-CSF in 72 adult healthy volunteers.
We also analyzed the pharmacokinetics using a two-compartment model with zero-order absorption and first-order elimination, according to the population pharmacokinetic manner, using the nonlinear mixed-effect model (NONMEM) program. 
SUBJECTS AND METHODS
Study Protocol and Subjects
The two clinical studies (Study 1 and Study 2) were performed in 1993 and 1997, respectively, and the objectives were to confirm the bioequivalence of four kinds of lenograstim formulation. The results showed that their pharmacokinetic properties are identical on the basis of the evidence obtained from the moment analysis method.
In accordance with the protocol, the subjects were administered 1 µg/kg of lenograstim subcutaneously in the forearm at 9 a.m. twice with the interval of 2 weeks. The study design was a 2 × 2 crossover. The subjects were divided into two groups and administered two kinds of formulation in different orders.
A total of 48 (Study 1) and 24 (Study 2) healthy adult male Japanese volunteers were selected after a thorough check of their medical histories and physical examinations. Admission criteria included normal laboratory parameters, including complete blood count, platelet count, prothrombin time, and activated partial thromboplastin generation time, as well as the absence of any evidence of clinically significant cardiovascular, renal, hepatic, metabolic, gastrointestinal, neurologic, or endocrine disorders. Each subject gave his written consent after having been informed of the contents of the study protocol, which had been approved by the Institutional Review Board of the clinical center, the Kannondai Clinic (Ibaraki, Japan).
Demographic data for age, height, and weight were not significantly different between the two studies, and the population means in Studies 1 and 2 were 21.9 and 22.0 years, 170.7 and 171.9 cm, and 62.4 and 61.8 kg, respectively. However, there was a significant difference in neutrophil count before administration, as shown in Table I .
Sample Collection and Drug Analysis
Venous blood was collected into tubes 1 hour before and at 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 48, and 72 hours after each administration. Blood samples were centrifuged for 30 minutes after collection at room temperature, and sera were harvested and stored frozen until analysis.
Serum G-CSF concentration was assayed using the enzyme-linked immunosorbent assay (ELISA) method, described as follows: Study 1: Serum G-CSF concentration was assayed in accordance with the method 7 developed at Chugai Pharmaceutical Co., Ltd. Study 2: Serum G-CSF concentration was assayed using the Quantikine™ human G-CSF immunoassay manufactured by R&D System (United Kingdom).
Serum rhG-CSF concentration was calculated from the serum G-CSF concentration minus the serum G-CSF concentration 1 hour before administration.
Noncompartmental Pharmacokinetic Analysis
Area under the curve for hours 0 to 72 (AUC 0-72 ), maximum serum concentration (C max ), time to reach C max (t max ), elimination rate constant for hours 4 to 12 (ke [4] [5] [6] [7] [8] [9] [10] [11] [12] ), and elimination rate constant for hours 12 to 72 (ke 12-72 ) were calculated in each administration period for each subject. AUC 0-72 was calculated using the linear trapezoidal rule.
Pharmacokinetic Analysis by NONMEM
We adopted a two-compartment model with zeroorder absorption and first-order elimination to describe the serum concentration-time profile of rhG-CSF after preliminary examination.
Taking R 0j , k 12j , k 21j , ke j , V 1j , and F j as the rate of absorption (ng/h -1 ), the transfer rate constant from compartment 1 to 2 (h -1 ), the transfer rate constant from compartment 2 to 1 (h -1 ), the elimination rate constant (h -1 ), the distribution volume of compartment 1 (L), and bioavailability, respectively, in the jth individual,
2 , R j = R 0j (when t i < F j Dose j /R 0j or 504 ≤ t i < F j Dose j /R 0j + 504) = 0 (when F j Dose j /R 0j ≤ t i < 504 or F j Dose j /R 0j + 504 ≤ t i ), Dose j = 1000 WT j (WT: body weight in kg), where t i is the time after the first administration, and C ij , X 1ij , and X 2ij are the serum rhG-CSF concentration (ng/L) and the amount of rhG-CSF in compartments 1 and 2 (ng), respectively, in the jth individual at time t i .
HAYASHI ET AL
To quantify the inter-and intraindividual variabilities, the nonlinear mixed effect model was constructed for data analysis. The additive and proportional error models are typical parametric models for describing a distribution of error. On the basis of a preliminary study's results based on the objective function, we chose the proportional error model for both the intra-and interindividual error models: 
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where η (R0/F) , η k12 , η k21 , η ke , and η (V1/F) are individual random perturbations from the population mean parameters that are independent and normally distributed with mean zero and variances equal to ω ( / ) 
Calculation of Increase in Neutrophil Count
Hematological examination was also performed at the same time points with the serum G-CSF concentration assay, and the neutrophil count was calculated from white blood cell count and the differential. The time course of the neutrophil count is shown in Figure 1 . The neutrophil count decreased after administration, and the nadir appeared around 1.0 hours after and then increased up to about 12 hours after administration.
The increase in the neutrophil count was calculated from the maximum minus the minimum values of the neutrophil count measured after administration.
Data Analysis
Computation for pharmacokinetic analysis was carried out using the NONMEM program (version 4, level 1.1) and a NM-TRAN preprocessor with a usersupplied PRED subroutine. NONMEM computes statistical data, called the minimum value of the objective function, equal to the negative value of twice the log likelihood on the assumption that distributions of random variables are normal. 8 A null hypothesis can be examined by comparing the values of the objective function. This difference in the values of the objective function (-2l.l.d.) with freedom is asymptotically distributed as χ 2 , with degrees of freedom equal to the number of parameters fixed to hypothesized values.
The correlation analysis was performed using the CORR procedure, and analysis of covariance (ANOCOVA) and analysis of variance (ANOVA) were performed using the GLM procedure of SAS (release 6.11). ANOCOVA was conducted to examine the correlation between pharmacokinetic parameters and the increase in the neutrophil count without the effect of difference in the study and administration period.
The statistically significant level was defined as p < 0.05 for all analysis.
RESULTS
Noncompartmental Pharmacokinetics and Increase in Neutrophil Count
The computed pharmacokinetic parameters are shown in Table I . There was a difference of 53.3% in ke [4] [5] [6] [7] [8] [9] [10] [11] [12] between Studies 1 and 2. There was also a difference of 40.1% in the neutrophil count before administration, and there was a significant correlation (r = 0.41562; p = 0.0001, correlation test and ANOCOVA; n = 143) between ke 4-12 and the neutrophil count before administration. Therefore, the reason for the difference in ke 4-12 might be due to the difference in the neutrophil count before administration. There was also a significant difference in C max , but this difference was only 16.3%.
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The correlations of AUC 0-72 , C max , and ke [4] [5] [6] [7] [8] [9] [10] [11] [12] with the increase in the neutrophil count are shown in Figure 2 for each study and period. There was no significant correlation between C max and the increase in the neutrophil count (Figure 2a) . There was also a weak correlation between AUC 0-72 and the increase in the neutrophil count (Figure 2b) . When all values were collected for analysis, the correlation coefficient was -0.18740, and the p-value was 0.0250 with the correlation test and 0.0172 with ANOCOVA. There was a significant correlation between ke 4-12 and the increase in the neutrophil count (Figure 2c ). There was no correlation between ke 12-72 and the increase in the neutrophil count.
Pharmacokinetic Analysis by NONMEM and Increase in Neutrophil Count
In a preliminary examination, we assumed the difference in the population mean of ke between studies. As a result, the objective function (OBJ) decreased to 15036.335 from 15102.322. The -2l.l.d. was 65.987, with p < 0.0001. Also, OBJ was 15707.092 when the absorption process was assumed to be a first-order process. There was no difference in freedom, but the -2l.l.d. was 670.757, and this should be sufficiently large for it to be considered as significant.
The computed population means of pharmacokinetic parameters are shown in Table II . The pharmacokinetic parameters for the intravenous administration of rhG-CSF (0.05-2.01 µg/kg), from Kuwabara et al, 9 are also included in this table. All pharmacokinetic parameters other than V 1 /F are close to that in the reference.
The time course estimated using the population means and the observed values is plotted in Figure 3 . The predicted and observed values seem to follow the same time course. The correlation between the Bayes estimated values and the predicted values is shown in Figure 4 and the weighted WRE are shown in Figure 5 . The WRE distributed symmetry, and there was no change with time. On the basis of these results, the pharmacokinetic model, a two-compartment model with zero-order absorption and first-order elimination, should be suitable for rhG-CSF subcutaneous administration.
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The correlation between Bayes estimated ke and the increase in the neutrophil count is shown in Figure 6 . The increase was an average of the periods after the first and second administrations.
The correlation coefficient was 0.60129 (p = 0.0001 by correlation test and ANOCOVA). This means that an individual with a high elimination rate constant shows a high increase in neutrophil count after administration.
DISCUSSION
The dose dependency of pharmacodynamic response (increase in neutrophil count) is well known. 10, 11 However, there was no correlation of C max and a negative correlation of AUC to the increase in neutrophil when the dose was fixed at 1 µg/kg.
The reason for this is probably based on the correlation of the elimination rate constant (ke) with the increase. The saturable and nonsaturable processes are involved in the elimination of G-CSF, and the ratio of saturable to total clearance is 76%. Also, the G-CSF receptor on the bone marrow cells is thought to have an important role in saturable clearance on the basis of in vivo pharmacokinetic analysis. 9 Therefore, the elimination of G-CSF by the G-CSF receptor should be faster in individuals with higher ke. Also, if the signal via the G-CSF receptor is stronger, the increase in neutrophil count should be higher. When rG-CSF is administered repeatedly, rhG-CSF clearance is known to 590 • J Clin Pharmacol 1999;39:583-592 HAYASHI ET AL increase, and there was a positive correlation between the increased clearance and neutrophil count. 10, 11 In this study, it was revealed that a positive correlation exists before the first administration.
The reason for the negative correlation between the AUC and the neutrophil count is that the AUC should indicate the rhG-CSF remainder, that is, the proportion that is not consumed in the course of increasing the neutrophil count. The AUC is proportional to the absorbed rhG-CSF amount and reciprocally proportional to clearance, and the absorbed rhG-CSF amount should have a positive correlation with the pharmacokinetic reaction. Therefore, the AUC should show a positive correlation to the pharmacodynamic reaction in ordinary cases. However, clearance of rhG-CSF has a positive correlation to the pharmacodynamic reaction, and its influence on the AUC is more than that of the rhG-CSF absorbed amount.
Bioavailability is used for multiple purposes, such as comparing several formulations. However, the bioavailability calculated from the AUC is not a good pharmacokinetic indicator of the formulation properties of such a pharmaceutical as rhG-CSF. In this situation, the pharmacodynamic reaction should be used as an indicator of the formulation properties, if possible. The bioavailability calculated from the AUC should be used carefully for other purposes.
Also, we analyzed the pharmacokinetics using a two-compartment model with zero-order absorption and first-order elimination in a population pharmacokinetic manner. This model was enough to obtain a good curve fit, and the population means of pharmacokinetic parameters were similar to ones reported for intravenous administration. 9 From these results, the absorption process should be not a first-order but a zero-order process. This is also supported by the t max being extended to 7.0 hours (CV: 18.4%, 4.3 hours for 1 µg/kg) when 2 µg/kg of rhG-CSF was administered (inhouse data). In other papers, 10 ,11 the pharmacokinetic analysis of subcutaneous administration was also conducted by using a model with a zero-order absorption.
The elimination of rhG-CSF is known to be a combination of saturable and nonsaturable processes. However, the first-order elimination model was sufficient to explain the dose of 1 µg/kg.
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